Growmax investments outstanding and monetizedGrowmax made some great investments in 2020-2021.
They bought and sold a whack of AGN for a great profit.
They also bought HAVN Life Sciences and made a huge profit.
TSX Venture Exchange has accepted for filing documentation in respect of the Company's April 2020 arm's length acquisition of 4,000,000 units in the capital of HAVN Life Sciences Inc. at $0.25per unit pursuant to a subscription agreement. Each unit comprised of 1 common share and 1 share purchase warrant, entitling the holder to purchase 1 additional common share at an exercise price of $0.50 per share for up to 2 years from the date of issuance. The Company also purchased 1,800,000 special warrants of HAVN Life Sciences Inc. at $0.02 per warrant. Each special warrant converted into 1 common share of HAVN Life Sciences Inc. on September 8, 2020 when HAVN Life Sciences Inc. became a publicly listed company. The Company's total cost of investment in HAVN Life Sciences Inc. was $1,036,000.
They now also hold Quality Green which is expected to list and trade in Q4 and they also have an investment in Pike Therapeutics which is supposed to list some time latee in the year. I hear the Quality Green placement is being re-priced.
TSX Venture Exchange has accepted for filing documentation in respect of the Company's May 2019 arm's length acquisition of 5,500,000 units in the capital of Quality Green Inc. at $0.55 per unit for a total cost of $3,025,000, pursuant to a seed round private placement of Quality Green Inc. Each unit comprised of 1 common share and 1 common share purchase warrant, entitling the holder to purchase 1 additional common share at an exercise price of $1.00 per share for up to 1 year from the date of issuance
https://www.piketx.com/meet-pike/board-management/:
Pike just did a placement at $.375 for $1.4M and is going to be listing in Q4 or Q1-2022. Pike has some very strong people on their team both for proudct development and market making in the trading of the company once it is public.
https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00049041
TSX Venture Exchange has accepted for filing documentation in respect of the Company's March 2020 arm's length acquisition of 1,000,000 common shares in the capital of Pike Therapeutics Inc. at CAD$0.13 per share for a total cost of CAD$133,000, pursuant to a subscription agreement.
Overall, I am told the company's objective is to make early stage investemnts and use the returns to build the NAV or to pay return of capitla if the opportunities do not offer themselves. At present the company is sitting on over $15M in cash and some very liquid holdings.